Copertura documentale

Il Quality Gate pubblico registra 9 supporti documentali, 3 fonti indipendenti e 5 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment — ClinicalTrials.gov
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. — ClinicalTrials.gov
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer — ClinicalTrials.gov
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies — ClinicalTrials.gov
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — ClinicalTrials.gov
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. — ClinicalTrials.gov
• Sapu003 in Advanced mTOR-sensitive Solid Tumors — ClinicalTrials.gov
• LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial — Crossref
• Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR — Crossref
• Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. — Europe PMC

Collegamenti nel Knowledge Graph

• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. — uses intervention
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer — uses intervention
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — uses intervention
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment — uses intervention
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 89/100 · ultimo aggiornamento Settembre 29, 2026